Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Sep;39(9):2296-2306.
doi: 10.1053/j.jvca.2025.05.050. Epub 2025 Jun 2.

Impact of Cardiopulmonary Bypass Duration on the Renal Effects of Amino Acids Infusion in Cardiac Surgery Patients

Collaborators, Affiliations
Randomized Controlled Trial

Impact of Cardiopulmonary Bypass Duration on the Renal Effects of Amino Acids Infusion in Cardiac Surgery Patients

Domenico Pontillo et al. J Cardiothorac Vasc Anesth. 2025 Sep.

Abstract

Objective: To test whether the duration of cardiopulmonary bypass (CPB) affects the nephroprotective effect of amino acids (AA) infusion in decreasing the occurrence of acute kidney injury (AKI) among cardiac surgery patients.

Design: A post hoc study of the PROTECTION multicenter randomized double-blind placebo-controlled trial aiming to assess the effect of CPB duration on the differential impact of AA infusion on both the absolute and relative risk reduction in AKI incidence by comparing medians of CPB duration and CPB duration as a continuous variable.

Setting: International, multicenter.

Participants: The entire population of the PROTECTION trial, comprising 3511 adult patients undergoing cardiac surgery with CPB.

Interventions: Intravenous AA infusion at a dosage of 2 g/kg/day, up to a maximum of 100 g/day.

Measurements and main results: Compared with patients with CPB duration above the median (prolonged [P]-CPB group), patients with CPB duration below the median (brief [B]-CPB group) had a significantly lower incidence of AKI (23% [n/N =391/1716] vs 36% [n/N = 617/1723]; relative risk [RR], 0.64; 95% confidence interval [CI], 0.57-0.71; p <0.001). However, in the P-CPB group, AA infusion achieved an 8% absolute risk reduction (32% vs 40%) and a 0.79 RR reduction (95% CI, 0.70-0.90; p < 0.001; number needed to treat, 14). Moreover, AA also decreased the occurrence of AKI stage 3 (2.2% [n = 19] vs 5.0% [n = 43]; RR, 0.45; 95% CI, 0.26-0.76; p < 0.001) with a >95% probability of this effect being significantly greater in the P-CPB group compared to the B-CPB group.

Conclusions: Cardiac surgery patients with prolonged CPB exposure had a significantly higher incidence of AKI. Notably, the P-CPB group received a greater benefit from AA therapy with an absolute risk and relative risk reduction of both any and severe AKI compared with the B-CPB group. Patients with prolonged CPB may be the specific targets of future studies.

Keywords: acute kidney injury; amino acids; anesthesia; cardiac surgery; cardiopulmonary bypass; intensive care.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types

MeSH terms

LinkOut - more resources